Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer.

Atish D. Choudhury,Lucia Kwak,Alexander Cheung,Abhishek Tripathi,Amanda Fredericks Pace,Eliezer M. Van Allen,Kerry L. Kilbridge,Xiao X. Wei,Bradley Alexander McGregor,Mark Pomerantz,Christopher Sweeney,Mary-Ellen Taplin,Heather A. Jacene,Glenn J. Bubley,Lauren C. Harshman,Lawrence Fong,Rupal S. Bhatt

Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer.

2021

Atish D. Choudhury
Lucia Kwak
Alexander Cheung
Abhishek Tripathi
Amanda Fredericks Pace
Eliezer M. Van Allen
Kerry L. Kilbridge
Xiao X. Wei
Bradley Alexander McGregor
Mark Pomerantz
Christopher Sweeney
Mary-Ellen Taplin
Heather A. Jacene
Glenn J. Bubley
Lauren C. Harshman
Lawrence Fong
Rupal S. Bhatt

98Background: Treatment (tx) options for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) to bone are limited. Radium-223 (R223) has demonstrated overall survival (OS) be...

Keywords:

overall survival
Oncology
Prostate cancer
castration resistant
Internal medicine
Radium-223
Pembrolizumab
Phases of clinical research
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations